中國醫藥大學機構典藏 China Medical University Repository, Taiwan:Item 310903500/920
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 29490/55136 (53%)
Visitors : 1522534      Online Users : 339
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cmu.edu.tw/ir/handle/310903500/920


    Title: 合成3-(5-甲基-2-呋喃基)-1,5-二苯基吡唑類衍生物作為抗血小板藥物;Synthesis of 3-(5-Methyl-2-furyl)-1,5-diphenylpyrazole Derivatives as Antiplatelet Agents
    Authors: 吳宗翰;Tsung-Han Wu
    Contributors: 中國醫藥大學:藥物化學研究所碩士班
    Keywords: ;;抗血小板;pyrazole;aniplatelet
    Date: 2009-07-09
    Issue Date: 2009-08-13 09:37:19 (UTC+8)
    Abstract: 在持續研發新型抗血小板的藥物過程中,發現3-(5-methyl-2- furyl)-1,5-diphenylpyrazole (I)具有優良的抗血小板活性,機轉為抑制cyclic nucleotide phosphodiesterase 5 (PDE5) (IC50 = 4.21 μM)。基於此結果,以化合物I為先導化合物,合成一系列1,5-substituted diphenyl-3-(5-methyl-2-furyl)pyrazole (4-11, 13-18, 21-26, 28-33, 35-40, 42-47)之相關衍生物。將所合成之化合物進行抗血小板活性評估,結果顯示化合物14, 15, 22, 23在人類富含血小板之血漿中,對於ADP (20 μM)及collagen (10 μg/ml)所誘導之血小板凝集表現出優良的抑制活性。以人類血小板懸浮液測試抗血小板凝集活性,化合物4 (IC50 = 0.28 μM)對於collagen (10 μg/ml)所誘導之血小板凝集抑制作用則優於化合物I (IC50 = 3.1 μM)。期待能開發出活性更佳之抗血小板藥物。

    In continuing development of novel aniplatelet agents, we had found that 3-(5-methyl-2-furyl)-1,5-diphenylpyrazole ( I) showed good platelet inhibitory activity. The mechanism is inhibition of cyclic nucleotide phosphodiesterase 5 (IC50 = 4.21 μM). Encouraged by this result, the compound I was selected as a lead compound and a series of 1,5- substituted diphenyl-3-(5-methyl-2-furyl)pyrazole derivatives (4-11, 13-18, 21-26, 28-33, 35-40, 42-47) were synthesized in this work. All the synthesized compounds were evaluated for their antiplatelet activities. The results revealed that compounds 14, 15, 22, 23 showed good inhibitory effects on platelet aggregation induced by ADP (20 μM) and collagen (10 μg/ml) in human platelet-rich plasma. In human platelet suspension, the inhibitory effect of compound 4 (IC50 = 0.28 μM) on platelet aggregation induced by collagen (10 μg/ml) was better than compound I (IC50 = 3.1 μM). The goal of our studies is for the development of novel potent antiplatelet agents.
    Appears in Collections:[Graduate Institute of Pharmaceutical Chemistry] Theses & dissertations

    Files in This Item:

    File SizeFormat
    index.html0KbHTML9View/Open


    All items in CMUR are protected by copyright, with all rights reserved.

     


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback